Table 2. Serum Levels of ADAM 8 and CEA according to GC Carcinogenic Sequence (Upper Panel) and between Non-Cancer and Cancer Groups (Lower Panel) in Validation Dataset.
| Groups (N) | Normal/Gastritis (70) | Dysplasia (24) | EGC (70) | AGC (50) | Metastasis (27) | p value* | Non-cancer groups (94) | Cancer groups (148) | p value† |
|---|---|---|---|---|---|---|---|---|---|
| Serum ADAM 8 (ng/mL) | 6.4±8.7 | 23.7±16.0 | 54.5±42.7 | 67.9±55.1 | 55.0±29.7 | <0.001 | 10.8±13.3 | 59.1±45.4 | <0.001 |
| Serum CEA (ng/mL) | 1.9±1.0 | 3.5±4.3 | 2.1±1.4 | 2.5±2.8 | 6.7±4.3 | <0.001 | 2.3±2.4 | 3.0±3.1 | 0.053 |
ADAM 8, a disintegrin and metalloproteinase domain 8; CEA, carcinoembryonic antigen; GC, gastric cancer; EGC, early gastric cancer; AGC, advanced gastric cancer. Values are expressed as mean±standard deviation.
*One-way analysis of variance test with multiple comparisons using post-hoc Bonferroni method was used to compare differences in means among disease groups; †An independent sample t-test was used to compare differences in means between non-cancer and cancer groups. p<0.05 (two-tailed) was considered statistically significant.